Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NGL Fine-ChemNSE:NGLFINE -1.02%78 Return-on-Tangible-Equity is 16.41% as of Mar. 2026, which is 9% below its 10-year median of 18.13. GuruFocus rates NSE:NGLFINE with a GF Score™ of 78/100 and a GF Value™ of ₹2,830.38 (Modestly Overvalued). The stock has 8 warning signs investors should review. Among 901 Drug Manufacturers companies, NGL Fine-Chem ranks better than 71.92% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. NGL Fine-Chem's annualized net income for the quarter that ended in Mar. 2026 was ₹539 Mil. NGL Fine-Chem's average shareholder tangible equity for the quarter that ended in Mar. 2026 was ₹3,288 Mil. Therefore, NGL Fine-Chem's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 16.41%.
The historical rank and industry rank for NGL Fine-Chem's Return-on-Tangible-Equity or its related term are showing as below:
NSE:NGLFINE'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 7.76 Med: 18.13 Max: 44.92
Current: 15.83
During the past 13 years, NGL Fine-Chem's highest Return-on-Tangible-Equity was 44.92%. The lowest was 7.76%. And the median was 18.13%.
NSE:NGLFINE's Return-on-Tangible-Equity is ranked better than 71.92% of 901
companies
in the Drug Manufacturers industry
Industry Median: 7.9
vs NSE:NGLFINE: 15.83
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
NGL Fine-Chem Return-on-Tangible-Equity Related Terms
NGL Fine-Chem Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for NGL Fine-Chem's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:NGLFINE vs LLY, JNJ, ABBV: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - General subindustry, NGL Fine-Chem's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NGL Fine-Chem Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, NGL Fine-Chem's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where NGL Fine-Chem's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 16.41% mean?
NGL Fine-Chem (NSE:NGLFINE) has a Return-on-Tangible-Equity of 16.41% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on NGL Fine-Chem and its competitors. This is near median its historical median of 18.13. Over the past decade, NGL Fine-Chem's Return-on-Tangible-Equity has ranged from 7.76 to 44.92. According to the industry distribution chart, NGL Fine-Chem ranks #253 out of 901 companies in the Drug Manufacturers industry, placing it in the top 28.1%.
Is NGL Fine-Chem's Return-on-Tangible-Equity too high?
NGL Fine-Chem's current Return-on-Tangible-Equity of 16.41% is near median its 10-year median of 18.13. Over the past 10 years, this metric has ranged from a low of 7.76 to a high of 44.92. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.90. NGL Fine-Chem's value of 16.41% is 107.7% above this industry median. Based on the distribution chart, NGL Fine-Chem ranks #253 out of 901 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, NGL Fine-Chem has a GF Score™ of 78/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NGL Fine-Chem's Return-on-Tangible-Equity compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, NGL Fine-Chem ranks #253 out of 901 companies for Return-on-Tangible-Equity. This puts NGL Fine-Chem in the upper half of its industry. The industry median Return-on-Tangible-Equity is 7.90. NGL Fine-Chem's value of 16.41% is 107.7% above this benchmark. Historically, NGL Fine-Chem's own Return-on-Tangible-Equity has ranged from 7.76 to 44.92 over the past decade. While the company's 10-year median is 18.13 vs. the industry median of 7.90, NGL Fine-Chem has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.90, based on 901 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NGL Fine-Chem's current Return-on-Tangible-Equity of 16.41% is 107.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on NGL Fine-Chem and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NGL Fine-Chem's current Return-on-Tangible-Equity is 16.41%, which is near median its own 10-year median of 18.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NGL Fine-Chem stock overvalued right now?
Based on GuruFocus' analysis, NGL Fine-Chem (NSE:NGLFINE) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹2,830.38, compared to a current price of ₹3,160.90 — trading 11.7% above its estimated fair value. The current Return-on-Tangible-Equity is 16.41%, which is near median its 10-year median of 18.13 and 107.7% above the Drug Manufacturers industry median of 7.90. NGL Fine-Chem's overall GF Score™ is 78/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For NGL Fine-Chem (NSE:NGLFINE), the current Return-on-Tangible-Equity is 16.41% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NGL Fine-Chem (NSE:NGLFINE) Overvalued in 2026?
Based on GuruFocus' analysis, NGL Fine-Chem stock appears to be overvalued.
The current stock price of ₹3,160.90 is trading 11.7% above its estimated GF Value™ of ₹2,830.38.
GuruFocus considers NGL Fine-Chem to be Modestly Overvalued.
Key valuation signals for NSE:NGLFINE:
Return-on-Tangible-Equity: 16.41% (near median its 10-year median of 18.13)
GF Value™: ₹2,830.38 vs. price of ₹3,160.90 (11.7% above fair value)
Industry Position: 107.7% above the Drug Manufacturers median (#253 of 901)
No single metric tells the full story. See the NSE:NGLFINE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NGL Fine-Chem Ltd is an Indian company engaged in the pharmaceutical business. It is a manufacturer of pharmaceuticals and intermediates for use in veterinary and human health, catering to various companies to custom-manufacture pharmaceuticals. The company's product portfolio comprises animal health APIs such as homidium chloride, nitroxynil, clorsulon, decoquinate, fenbendazole, etc.; human health APIs such as nitazoxanide and atovaquone; drug intermediates and specialty chemicals; and finished dosage forms such as diminazene aceturate granules and homidium chloride tablets. Geographically, the group generates maximum revenue from the Asia-Pacific region, and the rest from India, Europe, the USA, and the rest of the world.
78GF Score
Get the complete analysis for NSE:NGLFINE
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:NGLFINE has been successfully added to your 
